Korean J Urol.  2011 Jun;52(6):401-405.

Effect of Obesity on Prostate-Specific Antigen, Prostate Volume, and International Prostate Symptom Score in Patients with Benign Prostatic Hyperplasia

• Kim JM
• Song PH
• Kim HT
• Moon KH

Abstract

PURPOSE
We examined the correlation between body mass index (BMI) as a marker of obesity and prostate-specific antigen (PSA), prostate volume (PV), and International Prostate Symptom Score (IPSS) in patients with benign prostatic hyperplasia (BPH).
MATERIALS AND METHODS
From January 2008 to December 2008, we examined 258 patients diagnosed with BPH. Patients taking 5alpha-reductase inhibitors or those diagnosed with prostate cancer were excluded from this study. BPH was defined as PV> or =25 ml and IPSS> or =8. BMI (kg/m2) was categorized into 4 groups as follows: BMI<18.5 (underweight), BMI 18.5-23.0 (normal), BMI 23.0-27.5 (overweight), and BMI>27.5 (obese). The relationships between PSA, PV, IPSS, and BMI were analyzed by correlation analysis and one-way ANOVA.
RESULTS
The mean age of the patients was 65.19+/-9.13 years and their mean BMI was 23.7+/-4.4 kg/m2. The mean PSA values of each BMI group were as follows: 3.42+/-1.53, 3.07+/-1.88, 2.74+/-1.75, and 2.60+/-1.44 ng/ml. The PSA value was lowest in the obese group. The correlation analysis showed a negative correlation between BMI and PSA (Pearson's correlation coefficient=-0.142, p=0.023) and positive correlations between BMI and PV (Pearson's correlation coefficient=0.32, p=0.001) and IPSS (Pearson's correlation coefficient=0.470, p=0.02). These correlations were also confirmed by one-way ANOVA.
CONCLUSIONS
Patients with an elevated BMI tended to have lower PSA values, larger PVs, and a higher IPSS. We suggest that weight loss could be helpful for BPH symptom relief as well as for detection of coexisting prostate cancer in BPH patients.

Keyword

Analysis of variance; Body mass index; Prostatic hyperplasia

MeSH Terms

Analysis of Variance
Body Mass Index
Humans
Obesity
Prostate
Prostate-Specific Antigen
Prostatic Hyperplasia
Prostatic Neoplasms
Weight Loss
Prostate-Specific Antigen

Figure

• 

  FIG. 1 Univariate analysis by Pearson's correlation coefficient between BMI and PSA, PV, and IPSS. (A) Correlation between BMI and PSA (Pearson's correlation coefficient= -0.142, p=0.023), (B) Correlation between BMI and PV (Pearson's correlation coefficient=0.320, p=0.001), (C) Correlation between BMI and IPSS (Pearson's correlation coefficient=0.470, p=0.02). BMI: body mass index, PSA: prostate-specific antigen, PV: prostate volume, IPSS: International Prostate Symptom Score.

Reference

1. Rohrmann S, Smit E, Giovannucci E, Platz EA. Associations of obesity with lower urinary tract symptoms and noncancer prostate surgery in the Third National Health and Nutrition Examination Survey. Am J Epidemiol. 2004. 159:390–397.

2. Fowke JH, Signorello LB, Chang SS, Matthews CE, Buchowski MS, Cookson MS, et al. Effects of obesity and height on prostate-specific antigen (PSA) and percentage of free PSA levels among African-American and Caucasian men. Cancer. 2006. 107:2361–2367.

3. Rodriguez C, Patel AV, Calle EE, Jacobs EJ, Chao A, Thun MJ. Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev. 2001. 10:345–353.

4. Vollmer RT, Humphrey PA. Tumor volume in prostate cancer and serum prostate-specific antigen: analysis from a kinetic view-point. Am J Clin Pathol. 2003. 119:80–89.

5. Dubois D, Dubois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med. 1916. 17:863–871.

6. Boer P. Estimated lean body mass as an index for normalization of body fluid volumes in humans. Am J Physiol. 1984. 247:F632–F636.

7. Garza C, Haas J, Himes J, Pradilla A, Raman L, Seidell J, et al. Physical status: the use and interpretation of anthropometry: report of a WHO Expert Committee. Geneva. World Health Organ Tech Rep Ser. 1995. 854:1–452.

8. Bañez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, Rodriguez C, et al. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA. 2007. 298:2275–2280.

9. Hammarsten J, Högstedt B, Holthuis N, Mellström D. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 1998. 1:157–162.

10. Gupta A, Gupta S, Pavuk M, Roehrborn CG. Anthropometric and metabolic factors and risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans. Urology. 2006. 68:1198–1205.

11. Ozden C, Ozdal OL, Urgancioglu G, Koyuncu H, Gokkaya S, Memis A. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol. 2007. 51:199–203.

12. Xie LP, Bai Y, Zhang XZ, Zheng XY, Yao KS, Xu L, et al. Obesity and benign prostatic enlargement: a large observational study in China. Urology. 2007. 69:680–684.

13. Putnam SD, Cerhan JR, Parker AS, Bianchi GD, Wallace RB, Cantor KP, et al. Lifestyle and anthropometric risk factors for prostate cancer in a cohort of Iowa men. Ann Epidemiol. 2000. 10:361–369.

14. Rohrmann S, Smit E, Giovannucci E, Platz EA. Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Int J Obes (Lond). 2005. 29:310–316.

15. Joseph MA, Harlow SD, Wei JT, Sarma AV, Dunn RL, Taylor JM, et al. Risk factors for lower urinary tract symptoms in a population-based sample of African-American men. Am J Epidemiol. 2003. 157:906–914.

16. Hald T. Urodynamics in benign prostatic hyperplasia: a survey. Prostate Suppl. 1989. 2:69–77.

17. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004. 363:157–163.

18. Werny DM, Thompson T, Saraiya M, Freedman D, Kottiri BJ, German RR, et al. Obesity is negatively associated with prostate-specific antigen in U.S. men, 2001-2004. Cancer Epidemiol Biomarkers Prev. 2007. 16:70–76.

19. Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Weiss N, Goodman P, et al. Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. J Urol. 2007. 177:1395–1400.

20. Laven BA, Orsini N, Andersson SO, Johansson JE, Gerber GS, Wolk A. Birth weight, abdominal obesity and the risk of lower urinary tract symptoms in a population based study of Swedish men. J Urol. 2008. 179:1891–1895.

21. Park HK, Lee HW, Lee KS, Byun SS, Jeong SJ, Hong SK, et al. Relationship between lower urinary tract symptoms and metabolic syndrome in a community-based elderly population. Urology. 2008. 72:556–560.

22. Koo KC, Cho KS, Kang EM, Kwon SW, Hong SJ. The relationship between metabolic syndrome and prostate volume in men over sixties who underwent prostate health check-up. Korean J Urol. 2008. 49:813–817.

23. Lee SH, Kim JC, Lee JY, Kim JH, Oh CY, Lee SW, et al. Effects of obesity on lower urinary tract symptoms in Korean BPH patients. Asian J Androl. 2009. 11:663–668.

24. Freedland SJ, Platz EA, Presti JC Jr, Aronson WJ, Amling CL, Kane CJ, et al. Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. J Urol. 2006. 175:500–504.

25. Sohn JC, Lim MS, Chang HS, Park CH, Kim CI. The association of body mass index and prostate-specific antigen. Korean J Urol. 2007. 48:1121–1124.

26. Kim YD, Yang WJ, Song YS, Park YH. Correlation between prostate volume and metabolic or anthropometric factors in male visitors to a health promotion center. Korean J Urol. 2008. 49:139–144.

27. Kim GW, Doo SW, Yang WJ, Song YS. Effects of obesity on prostate volume and lower urinary tract symptoms in Korean men. Korean J Urol. 2010. 51:344–347.

28. Ochiai A, Fritsche HA, Babaian RJ. Influence of anthropometric measurements, age, and prostate volume on prostate-specific antigen levels in men with a low risk of prostate cancer. Urology. 2005. 66:819–823.

29. Dahle SE, Chokkalingam AP, Gao YT, Deng J, Stanczyk FZ, Hsing AW. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol. 2002. 168:599–604.